Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AOC 1001 in myotonic dystrophy type 1
NL-OMON58999Phase 3Completed
- Sponsor
- Avidity Biosciences
- Start
- Dec 2024
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of delpacibart etedesiran in myotonic dystrophy type 1 (DM1), sponsored by Avidity Biosciences. Primary endpoint: Change from baseline to Week 54 in video Hand Opening Time. Started Dec 2024; status: completed.
02
Drugs
delpacibart etedesiran
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NL-OMON58999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58999.